China's first 8-week hepatitis C treatment plan approved

2023-12-15 22:07:42
Medical Network March 21, the world's leading biopharmaceutical company Aibowei announced today that Weijianle® (Obi Pali Tablet) combined with Yiqirui® (Dasebide sodium tablets) hepatitis C treatment program has been in 2018 3 Approved by the China National Food and Drug Administration (CFDA) on the 2nd of the month to treat patients with type 1b, initial treatment, mild to moderate liver fibrosis (F0-F2) chronic hepatitis C, the course of treatment can be shortened to 8 weeks. China's first approved 8-week treatment plan. This is the second breakthrough that the program achieved in less than half a year after it was approved for listing in China in September 2017. The program is fully oral, interferon-free, and contains three direct antiviral drugs that inhibit the replication of hepatitis C virus against three major targets of the hepatitis C virus life cycle.
“The 8-week new treatments for the Weijianle® and Yiqirui® treatments were approved in China, again demonstrating the efforts of Abbott to provide innovative and effective treatments for Chinese patients with hepatitis C. We look forward to more Chinese patients with hepatitis C passing Optimized treatment plan to get rid of the disease as soon as possible.” Aibowei China General Manager Ou Silang said, “As one of the important players in the global hepatitis C field, Abbott will continue to introduce the latest products to the Chinese market. ”
The approval was supported based on a Phase 3b clinical study (GARNET) data. The results showed that patients with type 1b hepatitis C without cirrhosis (F0-F2) had a sustained virological response rate (SVR12) of 99% after 8 weeks of continuous treatment with the Vyclad® combined with the ichery® regimen (SVR12). n=147/148). [i]
Professor Wei Lai, director of the Institute of Liver Diseases, Peking University People's Hospital , said: "At present, the treatment cycle of direct hepatitis C anti-virus (DAAs) programs in China is generally more than 12 weeks. Obi Pali tablets (Vian Jianle®) The 5 weeks treatment of patients with genotype 1b, initial treatment, and cirrhosis-free (F0-F2) hepatitis C is the shortest to date for patients with type 1b, initial treatment, and cirrhosis-free (F0-F2). For these patients, drug exposure can be reduced. Reducing medical costs helps improve compliance."
Hepatitis C is a major public health challenge facing the world. There are about 10 million people infected with hepatitis C virus in China, of which gene type 1b is the most common, and the proportion of infected people is 56.8%.
"China's public awareness of hepatitis C is low, the detection rate is low, the diagnosis rate is low, and the treatment rate is lower. In 2017, more than 240,000 cases of hepatitis C patients were reported in China, and the situation of prevention and control is severe. Obi Paoli tablets Jianle®) combined with dexamebine sodium tablets (Isiri®) for 8-week treatment of patients with mild to moderate hepatic fibrosis type 1b hepatitis C will provide stronger support for the prevention and treatment of hepatitis C in China, promoting '2030 Eliminate the serious public health threat of viral hepatitis 'the realization of the goal." Professor Zhuang Hui, academician of the Chinese Academy of Engineering and honorary director of the Chinese Medical Association Liver Diseases Branch, said.
[i] Welzel TM, et al. Lancet Gastroenterol Hepatol. 2017 Jul; 2(7): 494-500
The original content has been revised.

Medicine Peptides

Medicine Peptides and protein drugs are emerging. There are now 35 important therapeutics on the market, and the development of biotechnology and biopharmaceutical companies is becoming increasingly global. Biotechnology drug research focuses on the application of DNA recombinant technology to develop peptides, proteins, enzymes, hormones, vaccines, cell growth factors and monoclonal antibodies that can be used in clinical applications. According to Parexl's Pharmaceutical R&D Statistical Source Book, there are currently 723 biotech drugs under FDA review (including phase â…° to iii clinical and FDA evaluation), 700 drugs are in early stage (research and preclinical). More than 200 additional drugs are in the final stage of approval (Phase iii clinical and FDA evaluation). The basic dosage form of biotech drugs is lyophilized. Although the efficacy of conventional preparations has long been clinically proven, they need to be injected frequently for a long time due to their short half-life, which is difficult to accept from the perspective of psychological and economic burden on patients. To this end, scholars around the world mainly from two aspects to study and develop convenient and reasonable drug delivery approaches and new preparations: (1) embedment agent and sustained-release injection. â‘¡ Non-injectable dosage forms, such as respiratory inhalation, rectal administration, nasal administration, oral administration and transdermal administration, etc. Injectable preparations of sustained-release biotechnological drugs are new dosage forms with promising applications. Some of them, such as microsphere injections of luteinizing hormone releasing hormone (LHRH) analogues which can be sustained-release for 1 to 3 months, have been on the market. This paper focuses on this kind of preparations.Main types of peptides and protein drug sustained-release preparations The research and development of peptides and protein drug sustained-release preparations can be divided into two types, namely, embedment agent and microsphere injection, from the perspective of development process and dosage form. The shape of the implant is a hollow micro-fine rod, one end is closed, the other end is open, and the rod material is non-biodegradable polymer such as ptfe. The lumen was filled with a mixture of drugs and silica gel (silastic, polydimethylsiloxane). The implant is embedded under the skin, and the drug is released slowly through the opening of silica gel matrix. The American Physicians' Handbook (PDR) contains a product called Norplant? Levo-18 ethyl norethinnes, used in family planning. The preparation, each with a diameter of 2.4 mm and a length of 34 mm, is surgically implanted in the inner side of the patient's upper arm with 6 thin rods. The drug can be released in the body in zero-grade mode for up to 5 years, and then removed by surgery after release,1.1.2 Micro-osmotic pump embedding agent The United States Alza company in the 1970s developed an embedding agent shaped like a capsule, which is embedded in the skin or other parts. The body fluid can penetrate through the shell, dissolve the interlayer electrolytic layer, make the volume expansion of the interlayer pressure to the plastic inner cavity, and promote the drug solution from the opening of the fixed speed release. Many biomolecular drugs, such as insulin, heparin and nerve growth factor, have been reported as model drugs in vivo and in vitro. Implants have positive significance for the treatment of chronic patients who need long-term medication, but it has the following defects: â‘  must be surgically implanted. â‘¡ The skeleton material of the preparation is non-biodegradable polymer, which needs to be removed by surgery after release. â‘¢ The preparation has irritation and discomfort in local tissues. Evaluation methods for polypeptide protein drugs: 1. Liquid chromatography 2. Spectroscopic 3. Solvent-based versions are easy to use, but need to be kept at low temperatures (2-8 degrees Celsius).

medicine peptides high,Peptide injections,buy medicine peptides high,medicine peptides for bodybuilding,medicine peptides for hgh

Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptidenootropics.com